Compugen Ltd. (USA)  

(Public, NASDAQ:CGEN)   Watch this stock  
Find more results for CGEN
7.08
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 6.10 - 10.02
Open     -
Vol / Avg. 0.00/163,189.00
Mkt cap 322.49M
P/E     -
Div/yield     -
EPS -0.31
Shares 50.25M
Beta 1.17
Inst. own 13%
Aug 7, 2015
Compugen Ltd Annual Shareholders Meeting (Estimated) - 3:00AM EDT - Add to calendar
Jul 27, 2015
Q2 2015 Compugen Ltd Earnings Release (Estimated) - 2:45AM EDT - Add to calendar
Jun 8, 2015
Compugen Ltd Investor and Analyst Meeting - 9:00AM EDT - Add to calendar
Jun 4, 2015
Compugen Ltd at Jefferies Global Healthcare Conference - 10:00AM EDT - Add to calendar
May 5, 2015
Q1 2015 Compugen Ltd Earnings Call
May 5, 2015
Q1 2015 Compugen Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1197.47% -89.71%
Operating margin -1232.36% -99.76%
EBITD margin - -94.44%
Return on average assets -22.05% -12.92%
Return on average equity -23.80% -16.08%
Employees 83 -
CDP Score - -

Address

72 Pinchas Rosen Street
TEL AVIV-YAFO, 6951294
Israel
+972-3-7658585 (Phone)
+972-3-7658555 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Compugen Ltd. is a drug discovery and development company. The initial fields of focus selected by the Company are monoclonal antibodies and therapeutic proteins to address unmet needs in the fields of oncology and immunology. Its business primarily involves collaborations covering the further development and commercialization of its discovered product candidates and various forms of research and discovery agreements. The Company’s pipeline Program consists of therapeutic product candidates at various stages, ranging from validation to pre-clinical studies. Under this Pipeline Program, newly discovered molecules enter the program when they begin experimental evaluation following their in silico prediction and selection. The Pipeline Program consists of in vitro and in vivo experimental validation, including animal disease model or similar testing, followed by various preclinical activities for selected molecules for up to an additional 18 months.

Officers and directors

Martin S. Gerstel Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Anat Cohen-Dayag Ph.D. President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Ari Krashin Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Zurit Levine Ph.D. Vice President - Research and Discovery
Age: 47
Bio & Compensation  - Reuters
John Hunter Vice President - Antibody Research & Development
Age: 52
Bio & Compensation  - Reuters
Dov Hershberg Director
Age: 75
Bio & Compensation  - Reuters
Yair Aharonowitz Ph.D. Independent External Director
Age: 74
Bio & Compensation  - Reuters
Ruth Arnon Independent Director
Age: 80
Bio & Compensation  - Reuters
Arie Ovadia Ph.D Independent External Director
Age: 66
Bio & Compensation  - Reuters
Joshua Shemer M.D. Independent External Director
Bio & Compensation  - Reuters